One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Access
PDF Availablehttps://doi.org/10.1136/jitc-2022-sitc2022.0606
Copy DOI
Export
Save
Share
Cite Journal: Journal for ImmunoTherapy of Cancer |  Publication Date: Nov 1, 2022 |
Affiliation: Bristol-Myers Squibb (United States), Dana-Farber Cancer Institute, Essen University Hospital, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Melanoma Institute Australia, University of Sydney, North Shore Hospital, Royal North Shore Hospital, Mater Health Services, The University of Texas MD Anderson Cancer Center, Sidney Kimmel Comprehensive Cancer Center, Bloomberg (United States)
BackgroundThe phase 2/3 RELATIVITY-047 clinical trial (NCT03470922) in patients with previously untreated metastatic or unresectable melanoma met its primary endpoint of improved progression-free survival with a combination of nivolumab plus...
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
